UnitedHealth posts profit above estimates, turnaround on track

UnitedHealth reported an adjusted EPS of $7.23 for the first quarter of 2026 and raised its full-year adjusted EPS outlook above $18.25, signaling progress in its turnaround plan. Shares rose roughly 6–7% in premarket trading after the results, and peers showed modest gains as investors reacted to the upbeat metrics.

The company increased its 2026 adjusted EPS target by $0.50 from the prior guidance (from greater than $17.75 to greater than $18.25), compared with an analyst consensus near $17.86, according to LSEG data. UnitedHealth management cited disciplined cost control and improved government payments as drivers of the quarter’s outperformance, while the CFO emphasized a prudent stance on guidance to preserve credibility.

On key operating metrics, the firm reported a medical cost ratio of 83.9% for the quarter versus analysts’ expectation of roughly 85.7%, reflecting lower-than-anticipated medical spending. Optum's operating income fell 15% to $3.3 billion, with Optum revenue at $24.1 billion and Optum Rx revenue at $35.7 billion, highlighting that the services unit remains under pressure even as insurance margins recover.

During the quarter UnitedHealth agreed to acquire Alegeus Technologies, sold its Optum UK business and announced plans to repurchase at least $2 billion of stock by the end of Q2. Management also outlined an expected decline of roughly 1.3 million Medicaid members, though it noted retention was slightly better than feared in some segments—an important variable for future margin performance.

Analysts say the results support the view that margins may have troughed in 2025 and that the company is taking steps to stabilize growth, but they caution that Optum's recovery and the trajectory of medical costs will determine whether the improvement is durable. In the near term, market attention will remain on membership trends, government payment dynamics and Optum’s operational reforms as indicators of sustained earnings momentum.